375 related articles for article (PubMed ID: 37138884)
1. Efficacy and safety of different JAK inhibitors in the treatment of alopecia areata: a network meta-analysis.
Wei D; Chen Y; Shen Y; Xie B; Song X
Front Immunol; 2023; 14():1152513. PubMed ID: 37138884
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and Safety of Baricitinib in Patients with Severe Alopecia Areata over 52 Weeks of Continuous Therapy in Two Phase III Trials (BRAVE-AA1 and BRAVE-AA2).
Kwon O; Senna MM; Sinclair R; Ito T; Dutronc Y; Lin CY; Yu G; Chiasserini C; McCollam J; Wu WS; King B
Am J Clin Dermatol; 2023 May; 24(3):443-451. PubMed ID: 36855020
[TBL] [Abstract][Full Text] [Related]
3. Janus Kinase Inhibitors for the Treatment of Severe Alopecia Areata: An Open-Label Comparative Study.
Almutairi N; Nour TM; Hussain NH
Dermatology; 2019; 235(2):130-136. PubMed ID: 30566941
[TBL] [Abstract][Full Text] [Related]
4. The efficacy and safety of JAK inhibitors for alopecia areata: A systematic review and meta-analysis of prospective studies.
Yan D; Fan H; Chen M; Xia L; Wang S; Dong W; Wang Q; Niu S; Rao H; Chen L; Nie X; Fang Y
Front Pharmacol; 2022; 13():950450. PubMed ID: 36091777
[No Abstract] [Full Text] [Related]
5. Efficacy and safety of the oral Janus kinase inhibitor baricitinib in the treatment of adults with alopecia areata: Phase 2 results from a randomized controlled study.
King B; Ko J; Forman S; Ohyama M; Mesinkovska N; Yu G; McCollam J; Gamalo M; Janes J; Edson-Heredia E; Holzwarth K; Dutronc Y
J Am Acad Dermatol; 2021 Oct; 85(4):847-853. PubMed ID: 34090959
[TBL] [Abstract][Full Text] [Related]
6. Janus Kinase Inhibitors for Alopecia Areata: A Systematic Review and Meta-Analysis.
Liu M; Gao Y; Yuan Y; Yang K; Shen C; Wang J; Tian J
JAMA Netw Open; 2023 Jun; 6(6):e2320351. PubMed ID: 37368402
[TBL] [Abstract][Full Text] [Related]
7. JAK inhibition in the treatment of alopecia areata - a promising new dawn?
Ismail FF; Sinclair R
Expert Rev Clin Pharmacol; 2020 Jan; 13(1):43-51. PubMed ID: 31865802
[No Abstract] [Full Text] [Related]
8. Treatments for Moderate-to-Severe Alopecia Areata: A Systematic Narrative Review.
Egeberg A; Linsell L; Johansson E; Durand F; Yu G; Vañó-Galván S
Dermatol Ther (Heidelb); 2023 Dec; 13(12):2951-2991. PubMed ID: 37833617
[TBL] [Abstract][Full Text] [Related]
9. Janus kinase inhibitors for alopecia areata.
King BA; Craiglow BG
J Am Acad Dermatol; 2023 Aug; 89(2S):S29-S32. PubMed ID: 37591562
[TBL] [Abstract][Full Text] [Related]
10. The Use of Janus Kinase Inhibitors in Alopecia Areata: A Review of the Literature.
Crowley EL; Fine SC; Katipunan KK; Gooderham MJ
J Cutan Med Surg; 2019; 23(3):289-297. PubMed ID: 30688081
[TBL] [Abstract][Full Text] [Related]
11. JAK inhibitors for alopecia areata: a systematic review and meta-analysis.
Phan K; Sebaratnam DF
J Eur Acad Dermatol Venereol; 2019 May; 33(5):850-856. PubMed ID: 30762909
[TBL] [Abstract][Full Text] [Related]
12. Janus kinase inhibitors: An innovative treatment for alopecia areata.
Park H; Yu DA; Kwon O
J Dermatol; 2019 Aug; 46(8):724-730. PubMed ID: 31237712
[TBL] [Abstract][Full Text] [Related]
13. [JAK INHIBITORS FOR THE TREATMENT OF ALOPECIA AREATA].
Ramot Y; Zlotogorski A
Harefuah; 2020 Jan; 159(1):38-42. PubMed ID: 31930807
[TBL] [Abstract][Full Text] [Related]
14. Role of janus kinase inhibitors in the treatment of alopecia areata.
Triyangkulsri K; Suchonwanit P
Drug Des Devel Ther; 2018; 12():2323-2335. PubMed ID: 30100707
[TBL] [Abstract][Full Text] [Related]
15. Emerging drugs for alopecia areata: JAK inhibitors.
Iorizzo M; Tosti A
Expert Opin Emerg Drugs; 2018 Mar; 23(1):77-81. PubMed ID: 29466675
[TBL] [Abstract][Full Text] [Related]
16. Novel investigational drugs for alopecia areata and future perspectives.
Chim I; Ghiya R; Sinclair RD; Eisman S
Expert Opin Investig Drugs; 2024 May; 33(5):441-449. PubMed ID: 38682280
[TBL] [Abstract][Full Text] [Related]
17. Review of Baricitinib in the Treatment of Alopecia Areata.
Singh R; Driscoll MS
J Drugs Dermatol; 2023 Sep; 22(9):935-940. PubMed ID: 37683061
[TBL] [Abstract][Full Text] [Related]
18. Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials.
King B; Mostaghimi A; Shimomura Y; Zlotogorski A; Choi GS; Blume-Peytavi U; Passeron T; Holzwarth K; Dutronc Y; McCollam J; Yang FE; Stanley S; Wu WS; Sinclair R
Br J Dermatol; 2023 Feb; 188(2):218-227. PubMed ID: 36763878
[TBL] [Abstract][Full Text] [Related]
19. Long-term efficacy and safety of baricitinib in patients with severe alopecia areata: 104-week results from BRAVE-AA1 and BRAVE-AA2.
Senna M; Mostaghimi A; Ohyama M; Sinclair R; Dutronc Y; Wu WS; Yu G; Chiasserini C; Somani N; Holzwarth K; King B
J Eur Acad Dermatol Venereol; 2024 Mar; 38(3):583-593. PubMed ID: 38391212
[TBL] [Abstract][Full Text] [Related]
20. A Review of JAK Inhibitors for Treatment of Alopecia Areata in the Military Health Care System.
Song CJ; Riley CA; Wilkison BD; Cho S
Mil Med; 2024 Jun; ():. PubMed ID: 38850223
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]